Winship's senior leadership together constitutes Its Executive Committee, the major decision-making body of the cancer center. The senior leadership has been assembled over the last decade, with a mission to define Winship's scientific priorities and provide oversight to their implementation. The group is led by Walter J. Curran, Jr., M.D., who was appointed Winship Executive Director in September 2009. Dr. Curran, a highly accomplished cancer physician and researcher, has broad authority over all cancer-related research, clinical and educational activities at Emory University. He led the development of a comprehensive strategic plan for Winship and devotes 50% of his time to Winship leadership and the administration of the Cancer Center Support Grant (CCSG). In October 2009, Dr. Curran appointed Fadlo R. Khuri, M.D., as Deputy Director of Winship, with responsibilities defined to include representing the center director at major university and health care functions and focusing on the scientific success and cross-fertilization of the research programs. Dr. Curran has assembled a highly effective team that includes Diane Cassels, M.S., Executive Administrator;Paul W. Doetsch, Ph.D., Associate Director for Basic Research;Edmund K. Waller, M.D., Ph.D., Associate Director for Clinical Research;Kimberiy Kerstann, Ph.D., Associate Director for Research Administration;Joseph Lipscomb, Ph. D., Associate Director for Population Sciences;and most recently, Deborah W. Bruner, Ph.D., R.N., Associate Director for Outcomes Research. Support is requested for all of the above individuals commensurate with their CCSG responsibilities. In addition, Rein Saral, M.D., an accomplished physician leader, serves as Associate Director for Community Affairs and Outreach, Charles Staley, M.D., a nationally prominent surgical oncologist serves as Associate Director for Clinical Affairs, and Dong M. Shin, M.D., a highly accomplished physician-scientist, is Associate Director for Academic Development. These individuals are supported by institutional funds, and no CCSG funds are requested. This group meets twice monthly and serves as the primary deliberative body that advises the Executive Director on major issues including the allocation of Winship's funds, space, and other resources. The Winship senior leadership has supported the development of a significant number of large multi-investigator grants, including a Head and Neck Cancer SPORE grant, several P01's, a large NASA center grant, and Emory's designation as a member of the NCI Chemical Biology Consortium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-05
Application #
8520229
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$216,929
Indirect Cost
$77,873
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Berg, Carla J; Stratton, Erin; Esiashvili, Natia et al. (2016) Young Adult Cancer Survivors' Experience with Cancer Treatment and Follow-Up Care and Perceptions of Barriers to Engaging in Recommended Care. J Cancer Educ 31:430-42
Patel, Kirtesh R; Chowdhary, Mudit; Switchenko, Jeffrey M et al. (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387-94
Horton, John R; Liu, Xu; Gale, Molly et al. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol 23:769-81
Yoshida, Michihiro; He, Peijian; Yun, C Chris (2016) Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One 11:e0154527
Bajpai, R; Matulis, S M; Wei, C et al. (2016) Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 35:3955-64
Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68
Owonikoko, Taofeek K; Zhang, Guojing; Kim, Hyun S et al. (2016) Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med 14:111
Xiao, Canhua; Miller, Andrew H; Felger, Jennifer et al. (2016) A prospective study of quality of life in breast cancer patients undergoing radiation therapy. Adv Radiat Oncol 1:10-16
Oliver, Daniel E; Patel, Kirtesh R; Switchenko, Jeffrey et al. (2016) Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 26:35-41
Liu, Min; Wang, Hongyan; Lee, Solah et al. (2016) DNA repair pathway choice at various conditions immediately post irradiation. Int J Radiat Biol 92:819-822

Showing the most recent 10 out of 210 publications